TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07075718: Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Sponsor: Glaukos Corporation · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 110 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07075718 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07075718 Rescue Dossier →